Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Cardiovascular disease is a major cause of mortality in patients with mild to moderate kidney disease and end stage renal disease [ESRD]. The principal reason to evaluate Dyslipidemia in patients with chronic kidney disease is to detect abnormalities that may be treated to reduce the incidence of cardiovascular disease. Dyslipidemia has been established as a well known traditional risk factor for cardiovascular disease in the General Population and large scale observational studies have shown that patients with impaired renal function exhibit significant alterations in lipoprotein metabolism. Data was collected from patients attending the Department of General Medicine of Sree Mookambika Institute of Medical sciences, kanyakumari, Tamil nadu, from march 2023 to September 2024. inclusion criteria are All newly detected Non diabetic Chronic kidney disease from Sep 2022 to Sep 2023. Age Group 15‐65 yrs. Impaired maturation of HDL in CKD is primarily due to down regulation of lecithin‐cholesterol acyltransferase and to a lesser extent, increase plasma cholesteryl ester transfer protein. Trigylceride enrichment of HDL in CKD is due to hepatic lipase deficiency and elevated CETP activity. The lipid abnormalities are found to occur in all stages of chronic kidney disease. The Reduction in HDL is the most observed lipid abnormality. The lipid abnormalities started to occur even in the earlier stages of chronic kidney disease. However the severity of chronic kidney disease did not correlate with the severity of lipid abnormalities and it was found to be statistically in significant.
How to cite this article:
R.V. Mookambika and M. Yokesh. Dyslipidemia in Chronic Kidney Disease Correlation to Stages of Chronic Kidney Disease: An Evaluation in a Tertiary Care Hospital.
DOI: https://doi.org/10.36478/makrjms.2025.3.88.92
URL: https://www.makhillpublications.co/view-article/1815-9346/makrjms.2025.3.88.92